Bristol-Myers Squibb: Hematologic Neoplasms trials

The registry lists 19 Hematologic Neoplasms studies with Bristol-Myers Squibb as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 11Phase 2 7Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological DisordersCompletedNCT02494258Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell MalignanciesCompletedNCT02061761Phase 1/2Results posted
• Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) MutationCompletedNCT01915498Phase 1/2Results posted
• Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With RuxolitinibTerminatedNCT01523171Phase 2Results posted
• Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With MyelofibrosisTerminatedNCT01437787Phase 3Results posted
• Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced CancerCompletedNCT01324323Phase 1Results posted
• Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced CancerCompletedNCT01324310Phase 1Results posted
• A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic CancersTerminatedNCT03783403Phase 1
• A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic NeoplasmsCompletedNCT02842229
• A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic CancersCompletedNCT02367196Phase 1
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
• Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological MalignanciesCompletedNCT02164071
• Phase 1 Study of CC-486 in Japanese Subjects With Hematological NeoplasmsTerminatedNCT01908387Phase 1
• Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic MalignancyWithdrawnNCT01452334Phase 1
• Study With SAR302503 in Patients With Polycythemia Vera or Essential ThrombocythemiaCompletedNCT01420783Phase 2
• Phase 2 Study of SAR302503 in Patients With MyelofibrosisCompletedNCT01420770Phase 2
• Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.CompletedNCT01353625Phase 1
• A Study of BMS-863233 in Patients With Hematologic CancerTerminatedNCT00838890Phase 1/2
• A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant DisordersStatus unknownNCT00596999